The most commonly reported adverse reactions associated with TARLIGE treatment in clinical trials are somnolence (15.4%), dizziness (10.1%) and oedema (6.7%).
Tabulated list of adverse reactions: Adverse reactions from TARLIGE in clinical trials, post-authorisation safety studies and spontaneous reporting are summarized in Table 7.
The following terminologies have been used in order to classify the occurrence of adverse reactions: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data). (See Table 7.)
Click on icon to see table/diagram/image
View ADR Monitoring Form